TrialBlood2025

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.

Armin Ghobadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.